Dr. Sergio Infante, MD

Dr. Infante practices at Loma Linda Univ Kidney Center - HOPD in Loma Linda, California.

Dr. Infante's NPI, 1962611897, was assigned on May 21, 2007. Dr. Infante graduated from El Bosque University in 1997. Dr. Infante holds California license A98495.

Dr. Infante's primary practice is Loma Linda Univ Kidney Center - HOPD, at 11375 Anderson St, Loma Linda, CA 92354.

Dr. Infante's primary practice is Loma Linda Univ Kidney Center - HOPD in Loma Linda, California. Dr. Infante is also affiliated with Loma Linda University Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Infante to 1 more hospital, 1 dialysis center, 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Infante's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Infante practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Infante's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Infante is board certified in internal medicine by the American Board of Internal Medicine. Dr. Infante is licensed in California.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances and kidney disease among the conditions Dr. Infante treats.

CMS data shows 740 Medicare services from Dr. Infante across 8 procedure codes in 2024, for 275 Medicare patients. Medicare paid $68,467 for them.

CMS counts 275 Medicare patients who saw Dr. Infante in 2024. The largest group is under 65, with 96 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 60% are also on Medicaid. Their average risk score is 5.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Infante's median patient age at 63, with 48% women.

In 2024, Dr. Infante wrote 1,025 Medicare Part D claims for 137 patients. 91% of them were for generic drugs. CMS names the drug for 826 of them, across 31 drugs with 11 or more claims each, at $88,972 in total drug cost. In 2023, CMS named 811 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Infante for performance year 2024, reported as part of a group. Dr. Infante accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Infante as offering telehealth.

Dmand AI links 5 papers to Dr. Infante, published from 2017 to 2020. 2020 was the busiest year, with 2. Dr. Infante has published most often in Nephrol Nurs J. Dr. Infante's most frequent co-authors are Amir Abdi Pour, MD, Smitha Reddy Anam, MD and Pedro Baron, MD.

CMS Open Payments shows 53 general payments to Dr. Infante from 23 drug and device companies from 2016 to 2025. Education make up the largest share, 42% of the total. Vantive US Healthcare LLC paid the most, $5,300.

Dr. Infante graduated from El Bosque University in 1997. Dr. Infante is a member of ACP and ASN.

Dr. Infante is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.